December 12, 2023 09:36 AM EST
Pharma
Marketing

Af­ter ground­break­ing year for RSV ap­provals, GSK looks to mod­el pe­di­atric suc­cess for adult vac­cines

Beth Snyder Bulik

Senior Editor

In vac­cine de­vel­op­ment, 2023 will be re­mem­bered for ma­jor strides in RSV with the first-ever ap­provals and now three dif­fer­ent op­tions. While that’s good news …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times